Revision as of 20:22, 6 November 2022

Preparedness

In India and the world/ 2018

Cancer preparedness in India and the world/ 2018
From: April 20, 2019: The Times of India

See graphic  :

Cancer preparedness in India and the world/ 2018

Research

2019/ JNCASR model helps study bone marrow, blood disorders

Chethan Kumar, April 13, 2019: The Times of India

A group of Indian researchers has created a mouse model to study bone marrow and blood disorders that could aid in finding a cure for blood cancer (leukaemia).

The team, led by Maneesha S Inamdar at Jawaharlal Nehru Centre for Advanced Scientific Research (JNCASR), has published its findings in ‘Blood’, a journal of the American Society of Haematology.

Inamdar, whose lab has discovered a stem cell protein called asrij (blood in Sanskrit), has found it plays a key role in preventing myelo-proliferative disease — a condition characterised by excessive production of mature blood cells.

Producing new blood cells is a lifelong activity. Given the sheer number of cells, they are prone to mutation which then becomes cancerous.

90% cancers caused by p53 mutation

Now, 90% of solid cancers are known to be caused by the mutation of p53, a protein that regulates cells production. In case of blood cancer, only 11% of the cancer was seen to be caused by p53 mutation. “Despite no significant mutation of p53, we found levels of asrij were low, causing uncontrolled production of new cells,” Inamdar told TOI.

Saloni Sinha, first author of the paper, said asrij protects p53, a cancer-preventing protein also known as the ‘Guardian of the Genome’. “Without asrij, p53 is destroyed and blood stem cells proliferate and become cancerous. It is known that mutations in p53 lead to cancer. However, scientists have been puzzled about how some cancers develop without a mutation in p53. Our work explains how this can happen,” Saloni said.

Will lead to new diagnostics

Inamdar said this could pave the way to new diagnostics and lead to the cure. To study how asrij works, the team designed a mouse that is engineered to mark the asrij gene for deletion. This was done in collaboration with the RIKEN CDB, Kobe, Japan and the National Centre for Biological Sciences, Bengaluru.

The Inamdar laboratory then deleted the marked region and showed that deleting one or both copies of the gene has no apparent effect, which was perplexing. Based on their earlier work, they predicted the mice are likely to develop blood cancer.

“Detailed experiments, including bone marrow transplants in mice, showed the mutants had too many blood stem cells, an enlarged spleen and developed severe myeloproliferative disease as they aged, just like human patients. The study could potentially revolutionise research seeking to find the origin and clinical progression of blood and other cancers. It will also lead to a search for drug treatments for a wide range of diseases affected by asrij and p53, including cancers and neuro-degenerative disorders,” said Inamdar.

CAR-T cells

Oct 23, 2022: The Times of India

Research and development on CAR-T cells
From: Oct 23, 2022: The Times of India

The safety trials for India’s first indigenously made CAR-T cells are a joint effort between IIT-Bombay and Tata Memorial Centre, Mumbai (the first patient was infused on June 6, 2021). This made-in-India therapy’s price tag will be a 10th of its cost in the US, said IIT-B scientist Rahul Purwar who is driving the project.


Last month, the group announced “encouraging” results of the Phase 1 trial for 10 patients with lymphoma. Last week, (Surg Cdr) Gaurav Narula from TMC announced similar results for the safety trial for six patients of leukemia at a medical conference in Kochi. “For a group of patients who had no known options, these were very encouraging results and in line with published data ofother CAR-T products in other parts of the world,” said Narula. Each of these patients had received three to five lines of therapy, including previous stem cell transplant, but in vain.


TMC deputy director Navin Khattry said although “it’s early days yet” with CAR-T cells, the Indian product has proved to be safe. “We found it has low toxicity as compared to the western CAR-T cells. For instance, 33% of the western patients develop some level of neurological toxicity, but this wasn’t seen in our patients. Moreover, none of our patients developed cytokine storms (when the body’s immune system responds too aggressively to infection),” said Khattry.


Another eight-year-old boy who underwent CAR-T infusion over six months back is also cancer-free at the moment. Only one of the six patients didn’t have any response to CAR-T cells. Another patient, who responded well initially, passed away 16 months later after undergoing abone marrow transplant.


Doctors hope the 8-yearold girl and other patients in the future have the same response as American youngster Emily Whitehead, who was the first patient in the world to undergo CAR-T cell therapy 10 years back. She didn’t need any therapy thereafter and has been cancer free since 2012.


According to the girl’s father, doctors first collected his daughter’s blood through a special process for collecting white blood cells.

Thereafter, her T cells were gathered from white blood cells and “trasduced” with a viral vector (tools used to deliver genetic material into cells). “This is done in order to get the T Cells to express certain antibody,” said Dr Narula.


These modified T Cells were then multiplied in the high-tech laboratory at IIT Bombay. A battery of tests was done to check for toxicity before it was given as a single infusion to the patient. 
“We were in ACTREC for 30 days and came back to Igatpuri,” said the father. She has go back for a checkup in early November.


As for the IIB-TMC team, it is preparing for the second phase of the clinical trial in which 50 patients will be given CAR-T cells. Purwar, who has since set up ImmunoACT Laboratory, said, “We are also working on gene therapy for various other cancers, including solid tumours,'” he said, adding that the goal is to make gene therapy affordable to many more Indians.

Homegrown CAR-T cells ‘cure’ 8-yr-old’s leukemia

Mumbai : Three months ago, an eight-year-old girl’s parents were told she had only a few more weeks to live as her leukemia had relapsed. Doctors at Tata Memorial Hospital, where she was under treatment since 2020, however, offered them an option: A homegrown version of a gene therapy that had shown promise in at least 50% of the patients it was used for in the West.


Her father, a driver in a village near Igatpuri, said there was no reason to turn down the new therapy as her condition was “bad” at that time. “CAR-T saved her,” he told TOI. When the family visitedACTREC, Tata Memorial Centre’s research block in Kharghar earlier in the week, doctors told them no cancer cells could be detected in the girl’s blood. “She is eating normally for the first time in two years,” he added.
CAR-T cells are a new form of immunotherapy, itself a fledgling branch of cancertreatment. It entails re-engineering the body's T immune cells with some genetic material so that they selectively target cancer cells for destruction. The 8-year-old got the treatment as part of the safety trials for India’s first indigenously made CAR-T cells.

Therapies

IIT-B’s immunotherapy using CAR T-cells

Yogita Rao, Dec 12, 2019 Times of India

In a breakthrough in research, IIT-Bombay scientists have developed technology to leverage a patient’s immune system to cure cancer. Such immunotherapy using CAR T-cells, a treatment for cancer, which costs Rs 3-4 crore in US, can be made available for Rs 15 lakh, if the technology is developed in the country.

Researchers made use of gene and cell therapies to reengineer immune cells to attack and kill cancer cells in the body. The treatment is less painful than surgery, chemotherapy or radiation, and is known to lower chances of a relapse. The therapy, which seems promising in the treatment of cancer, especially leukaemia, is currently not available in India. With the growing burden of cancer in the country, success in even a fraction of the patients using the technique will be remarkable, experts said.

Prof Rahul Purwar and his team of scientists from the institute’s Department of Biosciences and Bioengineering have conducted laboratory tests and hope to start clinical trials in collaboration with Dr Gaurav Narula from Tata Memorial Hospital next year, after getting permission from Drug Controller General of India.

T-cells (a type of white blood cell), an integral part of the immune system, can identify tumours and destroy them. But in advanced stages, the cancer cells adapt to the presence of T-cells and remain undetected. In the new approach in immunotherapy, called CAR (chimeric antigen receptors) T-cell therapy, the T-cell’s ability to detect and kill cancer cells is restored. CARs are protein that assist Tcells to recognise and attach to protein or antigen, present on cancer cells. These proteins help destroy cancer cells.

Treatment

Patients’ expenses in 2019

DurgeshNandan Jha, April 20, 2019: The Times of India

Distribution of medical and non-medical costs in cancer cases (in %), as in 2019
From: DurgeshNandan Jha, April 20, 2019: The Times of India

When it comes to the dreaded ‘C’, even the poorest of the families spend over Rs 50,000 towards treatment of their wards at public hospitals where consultation, surgery and key medicines are provided for free. This was revealed in a cost-analysis published in the journal, Psycho-Oncology.

Researchers from Australia’s McGill University, University of Sydney, University of Toronto and George Institute for Global Health, in partnership with CanKids, an NGO, interviewed 11 families of children being treated for cancer at AIIMS and Safdarjung Hospital.

Over half of the families’ primary income was generated from an unskilled-worker wage, and at least one parent per family was illiterate or had no formal schooling. Eight families were from outside the National Capital Region, according to the research paper.

In 14 weeks, a fortnight prior to the diagnosis and 12 weeks after the diagnosis of cancer, the families said they had spent Rs 51,644, on average. A maximum 53% of the money was spent on non-medical categories and 47% on medical needs.

Non-medical cost included travel, lodging, food and miscellaneous expenses. Medical cost involved chemotherapy, supportive care, surgery, radiation, investigations and transfusions. “The mean cost two weeks prior to the diagnosis was Rs 7,621 with 73% costs on medical and 27% on non-medical categories. The mean cost for 12 weeks following the diagnosis was Rs 44,023 with 42% on medical and 58% on non-medical categories,” the cost-analysis stated.

The researchers say, collectively, these costs are substantial, impose a catastrophic burden and impact employment, schooling and housing. “The study did not include the expenditures borne by the government in providing physician/nursing expertise, medications and investigations,” they added.

The researchers have called for hospital service providers to review their policies, procedures and service agreements to limit the financial burden imposed on families by encompassing a reasonable charge, consider families’ cost in the design of services, and ensure that provisions are in place to lower the economic burden.

A recent research published in the journal PlosOne found that out-of-pocket expenditure on cancer treatment was among the highest for any ailment.

The PlosOne research, conducted by experts from DU’s Institute of Economic Growth, which evaluated costs for all kinds of cancer, not just those involving children, said treatment for 40% of cancer hospitalisation cases is financed mainly through borrowings, sale of assets and contributions from friends and relatives.

The researchers suggested universal cancer care insurance, combined with existing accident and life insurance policies, for the poorer sections in India, in addition to policies to improve cancer survivorship through effective prevention and early detection.